These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 39012596)

  • 1. Protocol for Allele-Specific Epigenome Editing Using CRISPR/dCas9.
    Rajaram N; Bashtrykov P; Jeltsch A
    Methods Mol Biol; 2024; 2842():179-192. PubMed ID: 39012596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allele-Specific Epigenome Editing.
    Bashtrykov P; Jeltsch A
    Methods Mol Biol; 2018; 1767():137-146. PubMed ID: 29524132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of super-specific epigenome editing by targeted allele-specific DNA methylation.
    Rajaram N; Kouroukli AG; Bens S; Bashtrykov P; Jeltsch A
    Epigenetics Chromatin; 2023 Oct; 16(1):41. PubMed ID: 37864244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A.
    Huang YH; Su J; Lei Y; Brunetti L; Gundry MC; Zhang X; Jeong M; Li W; Goodell MA
    Genome Biol; 2017 Sep; 18(1):176. PubMed ID: 28923089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editing of DNA Methylation Using dCas9-Peptide Repeat and scFv-TET1 Catalytic Domain Fusions.
    Morita S; Horii T; Hatada I
    Methods Mol Biol; 2018; 1767():419-428. PubMed ID: 29524149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient Targeted DNA Methylation with dCas9-Coupled DNMT3A-DNMT3L Methyltransferase.
    Bashtrykov P; Rajaram N; Jeltsch A
    Methods Mol Biol; 2023; 2577():177-188. PubMed ID: 36173573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized Protocol for the Regulation of DNA Methylation and Gene Expression Using Modified dCas9-SunTag Platforms.
    Morita S; Horii T; Hatada I
    Methods Mol Biol; 2024; 2842():155-165. PubMed ID: 39012594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting oncogenic TERT promoter variants by allele-specific epigenome editing.
    Kouroukli AG; Rajaram N; Bashtrykov P; Kretzmer H; Siebert R; Jeltsch A; Bens S
    Clin Epigenetics; 2023 Nov; 15(1):183. PubMed ID: 37993930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo epigenome editing and transcriptional modulation using CRISPR technology.
    Lau CH; Suh Y
    Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of Cell Lines Stably Expressing dCas9-Fusions to Address Kinetics of Epigenetic Editing.
    Goubert D; Koncz M; Kiss A; Rots MG
    Methods Mol Biol; 2018; 1767():395-415. PubMed ID: 29524148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenome editing of the CFTR-locus for treatment of cystic fibrosis.
    Kabadi AM; Machlin L; Dalal N; Lee RE; McDowell I; Shah NN; Drowley L; Randell SH; Reddy TE
    J Cyst Fibros; 2022 Jan; 21(1):164-171. PubMed ID: 34049825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of Cell Lines Stably Expressing a dCas9-Fusion or sgRNA to Address Dynamics of Long-Term Effects of Epigenetic Editing.
    Sarno F; Koncz M; Eilers RE; Verschure PJ; Rots MG
    Methods Mol Biol; 2024; 2842():289-307. PubMed ID: 39012602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of Gene Expression Using dCas9-SunTag Platforms.
    Morita S; Horii T; Hatada I
    Methods Mol Biol; 2023; 2577():189-195. PubMed ID: 36173574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs.
    Pflueger C; Tan D; Swain T; Nguyen T; Pflueger J; Nefzger C; Polo JM; Ford E; Lister R
    Genome Res; 2018 Aug; 28(8):1193-1206. PubMed ID: 29907613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allele-specific genome targeting in the development of precision medicine.
    Wu J; Tang B; Tang Y
    Theranostics; 2020; 10(7):3118-3137. PubMed ID: 32194858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review.
    Syding LA; Nickl P; Kasparek P; Sedlacek R
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for DNA Methylation Editing of Imprinted Loci and Assessment of the Effects.
    Sekita Y; Kimura T
    Methods Mol Biol; 2024; 2842():167-178. PubMed ID: 39012595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locus-Specific and Stable DNA Demethylation at the
    Albrecht C; Rajaram N; Broche J; Bashtrykov P; Jeltsch A
    Genes (Basel); 2024 Jan; 15(1):. PubMed ID: 38254969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
    Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
    Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.